AbstractBySubCategory

Adoptive T-cell therapy: Modified and Unmodified Cells

Therapies Targeting T cells

2017 ASCO-SITC Clinical Immuno-Oncology Symposium

ABSTRACT TITLE FIRST AUTHOR ABSTRACT NO.sort descending
Gene expression signatures of response to anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in patients with CLL and ALL. Elena Orlando

137

The impact of checkpoint blockade prior to adoptive cell therapy using tumor-infiltrating lymphocytes for metastatic melanoma: An update from MD Anderson Cancer Center. Marie-Andree Forget

138

Chimeric antigen receptor (CAR) T cells genetically engineered to deliver IL-12 to the tumor microenvironment in ovarian cancer. Oladapo O. Yeku

141

Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer. Michael Adam Poch

142

Modulating lncRNA NKILA in tumor-reactive T cells to enhance their trafficking to breast cancer by inhibition of FasL-induced T-cell apoptosis. Di Huang

143

Effect of dendritic cells (DC) transduced with chimeric antigen receptor (CAR) on CAR T-cell cytotoxicity. Hyung Chan Suh

144

Generation and characterization of antitumor infiltrating lymphocytes from patients with breast cancer for adoptive cell transfer therapy. Juhua Zhou

145

Suppression of EBV-induced LCLs using CAR T cells redirected against HLA-DR. Chungyong Han

146

Final report of a pilot trial combining ipilimumab and adoptive cell therapy. John Mullinax

147

CD70 as a novel target of CAR-T-cell therapy for gliomas. Linchun Jin

148

Development of a novel T-cell immunotherapy targeting HEATR1. Robson Grando Dossa

149

Development of human NKG2D-CD3ε chimeric antigen receptor (CAR) for T-cell-mediated cancer immunotherapy. Sergei Kusmartsev

150

Antigen-dependent costimulation to improve T-cell therapy for cancer. Christopher C. DeRenzo

151

Combinatorial IL13Rα2 chimeric antigen receptor-T cells plus checkpoint blockade to treat solid tumors in murine and canine models. Yibo Yin

152